SI1135391T1 - Novel triazolo(4,5-d)pyrimidine compounds - Google Patents

Novel triazolo(4,5-d)pyrimidine compounds

Info

Publication number
SI1135391T1
SI1135391T1 SI9930550T SI9930550T SI1135391T1 SI 1135391 T1 SI1135391 T1 SI 1135391T1 SI 9930550 T SI9930550 T SI 9930550T SI 9930550 T SI9930550 T SI 9930550T SI 1135391 T1 SI1135391 T1 SI 1135391T1
Authority
SI
Slovenia
Prior art keywords
pyrimidine compounds
novel triazolo
triazolo
novel
pyrimidine
Prior art date
Application number
SI9930550T
Other languages
English (en)
Slovenian (sl)
Inventor
Simon Astra Charnwood Guile
David Astra Charnwood Hardern
Anthony Astra Charnwood Ingall
Brian Astra Charnwood SPRINGTHORPE
Paul Astra Charnwood WILLIS
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1135391(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9804211A external-priority patent/SE9804211D0/xx
Priority claimed from SE9901271A external-priority patent/SE9901271D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SI1135391T1 publication Critical patent/SI1135391T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/40—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI9930550T 1998-12-04 1999-12-02 Novel triazolo(4,5-d)pyrimidine compounds SI1135391T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9804211A SE9804211D0 (sv) 1998-12-04 1998-12-04 Novel compounds
SE9901271A SE9901271D0 (sv) 1999-04-09 1999-04-09 Novel compounds
EP99963796A EP1135391B1 (en) 1998-12-04 1999-12-02 Novel triazolo(4,5-d)pyrimidine compounds
PCT/SE1999/002256 WO2000034283A1 (en) 1998-12-04 1999-12-02 Novel triazolo(4,5-d)pyrimidine compounds

Publications (1)

Publication Number Publication Date
SI1135391T1 true SI1135391T1 (en) 2004-08-31

Family

ID=26663448

Family Applications (3)

Application Number Title Priority Date Filing Date
SI9931026T SI1386921T1 (sl) 1998-12-04 1999-12-02 Intermediati za pripravo antitrombotičnih 4H-ciklopenta-1,3-dioksolnih derivatov
SI9931059T SI1386917T1 (sl) 1998-12-04 1999-12-02 Intermediati za pripravo nekaterih triazolopirimidinov kot P2T antagonistov
SI9930550T SI1135391T1 (en) 1998-12-04 1999-12-02 Novel triazolo(4,5-d)pyrimidine compounds

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SI9931026T SI1386921T1 (sl) 1998-12-04 1999-12-02 Intermediati za pripravo antitrombotičnih 4H-ciklopenta-1,3-dioksolnih derivatov
SI9931059T SI1386917T1 (sl) 1998-12-04 1999-12-02 Intermediati za pripravo nekaterih triazolopirimidinov kot P2T antagonistov

Country Status (36)

Country Link
US (12) US6525060B1 (el)
EP (5) EP1386917B1 (el)
JP (4) JP4202607B2 (el)
KR (4) KR100776484B1 (el)
CN (1) CN1128801C (el)
AR (3) AR023920A1 (el)
AT (3) ATE513816T1 (el)
AU (1) AU766618B2 (el)
BR (1) BRPI9915883B8 (el)
CA (1) CA2351709C (el)
CY (3) CY1110501T1 (el)
CZ (3) CZ295234B6 (el)
DE (4) DE69915675D1 (el)
DK (3) DK1386917T3 (el)
EG (1) EG24814A (el)
ES (3) ES2366902T3 (el)
FR (1) FR11C0016I2 (el)
HK (3) HK1061246A1 (el)
HU (2) HU228589B1 (el)
ID (1) ID29927A (el)
IL (6) IL143232A0 (el)
LT (1) LTC1135391I2 (el)
LU (1) LU91819I2 (el)
MY (1) MY121867A (el)
NO (3) NO319806B1 (el)
NZ (1) NZ511778A (el)
PL (1) PL201283B1 (el)
PT (2) PT1386921E (el)
RU (3) RU2317990C2 (el)
SA (1) SA99200848B1 (el)
SI (3) SI1386921T1 (el)
SK (1) SK286007B6 (el)
TR (1) TR200101567T2 (el)
TW (1) TWI229674B (el)
WO (1) WO2000034283A1 (el)
ZA (1) ZA200104094B (el)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9903290D0 (sv) * 1999-09-15 1999-09-15 Astra Pharma Prod Novel compounds
SE9904129D0 (sv) 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
TWI290549B (en) * 2000-06-02 2007-12-01 Astrazeneca Ab Process for the preparation of cyclopropyl carboxylic acid ester and derivatives
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
GB0013488D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
CN100471842C (zh) 2003-07-24 2009-03-25 安斯泰来制药有限公司 喹诺酮衍生物或其盐
SE0401001D0 (sv) 2004-03-31 2004-03-31 Astrazeneca Ab Chemical process
SE0400873D0 (sv) 2004-03-31 2004-03-31 Astrazeneca Ab Chemical process
JPWO2007020935A1 (ja) * 2005-08-17 2009-02-26 小野薬品工業株式会社 Ｐ２ｙ１２受容体および／またはｐ２ｙ１４受容体ブロッカーを含有してなる疼痛治療剤
TWI391378B (zh) 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
GB0615620D0 (en) 2006-08-05 2006-09-13 Astrazeneca Ab A process for the preparation of optically active intermediates
WO2008024044A1 (en) * 2006-08-21 2008-02-28 Astrazeneca Ab Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
JP2010508350A (ja) 2006-10-31 2010-03-18 ヤンセン ファーマシューティカ エヌ．ベー． Ａｄｐｐ２ｙ１２レセプターアンタゴニストとしてのトリアゾロピリミジン誘導体
TWI496776B (zh) * 2007-11-15 2015-08-21 Astrazeneca Ab 製備(3aR,4S,6R,6aS)-6-胺基-2,2-二甲基四氫-3aH-環戊并[d][1,3]二氧雜環戊烯-4-醇之純非對映異構性之二苯甲醯-L-酒石酸鹽之方法
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
TWI389913B (zh) * 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
US8563755B2 (en) 2008-09-09 2013-10-22 Astrazeneca Ab Process for preparing [1S-[1-α, 2-α, 3-β(1S*,2R*) 5-β]]-3-[7-[2-(3,4-difluorophenyl)-cyclopropylamino]-5-(propylthio)-3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl]-5-(2-hydroxyethoxy) cyclopentane-1,2-diol and to its intermediates
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
EP2389362B1 (en) 2009-01-21 2019-12-11 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
WO2011017108A2 (en) * 2009-07-27 2011-02-10 Auspex Pharmaceuticals, Inc. Cyclopropyl modulators of p2y12 receptor
EP2305376A1 (en) 2009-09-23 2011-04-06 Lonza Ltd. Process and catalyst for the catalytic hydrogenation of aromatic and heteroaromatic nitro compounds
KR101736218B1 (ko) 2009-09-25 2017-05-16 오리존 지노믹스 에스.에이. 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
WO2011067571A1 (en) 2009-12-03 2011-06-09 Astrazeneca Ab Co - crystals of a triazolo [4,5 - d] pyrimidine platelet aggregation inhibitor
ES2550033T3 (es) 2009-12-23 2015-11-04 Ratiopharm Gmbh Forma de dosificación farmacéutica sólida de ticagrelor
US8859769B2 (en) 2010-02-16 2014-10-14 Actavis Group Ptc Ehf Processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
WO2011106105A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
ES2607081T3 (es) 2010-04-19 2017-03-29 Oryzon Genomics, S.A. Inhibidores de desmetilasa específica de lisina-1 y su uso
US20130150577A1 (en) 2010-04-20 2013-06-13 Actavis Group Ptc Ehf Novel process for preparing phenylcyclopropylamine derivatives using novel intermediates
CN103003231A (zh) 2010-06-30 2013-03-27 阿特维斯集团公司 制备苯基环丙基胺衍生物的新方法及其用于制备替卡格雷的用途
HUE037937T2 (hu) 2010-07-29 2021-11-29 Oryzon Genomics Sa Arilciklopropilamin-alapú LSD1-demetiláz inhibitorok és gyógyászati alkalmazásuk
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012063126A2 (en) 2010-11-09 2012-05-18 Actavis Group Ptc Ehf Improved processes for preparing pure (3ar,4s,6r,6as)-6-amino-2,2-dimethyltetrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol and its key starting material
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
RU2013133879A (ru) * 2010-12-20 2015-01-27 Актавис Груп Птс Ехф НОВЫЕ СПОСОБЫ ПОЛУЧЕНИЯ ТРИАЗОЛО[4, 5-d]ПИРИМИДИНА, ЕГО ПРОИЗВОДНЫЕ И ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ
WO2012107498A1 (en) 2011-02-08 2012-08-16 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative disorders
CN102653539B (zh) * 2011-03-01 2014-09-17 秦引林 一种抗血小板聚集化合物及其药物组合
CA2832570A1 (en) 2011-04-06 2012-10-11 Teva Pharmaceutical Industries Ltd. New intermediates and processes for preparing ticagrelor
CN102731510B (zh) * 2011-04-07 2015-12-16 博瑞生物医药（苏州）股份有限公司 替卡格雷的衍生物、制备方法及其药物用途
CZ2011229A3 (cs) * 2011-04-19 2012-08-15 Zentiva, K.S. Opticky aktivní soli (3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyklopenta-[d][1,3]dioxol-4-olu a zpusob jejich prípravy
MX2013013221A (es) 2011-05-13 2013-12-02 Astrazeneca Ab Proceso para la preparacion de [(3as, 4r, 6s, 6ar) -6- hidroxi-2, 2-dimetiltetrahidro-3ah-ciclopenta [d] [1, 3] dioxol-4-il] carbamato de bencilo e intermedios del proceso.
EP2741741A2 (en) * 2011-05-19 2014-06-18 Oryzon Genomics, S.A. Lysine demethylase inhibitors for inflammatory diseases or conditions
US20140296255A1 (en) * 2011-05-19 2014-10-02 Oryzong Genomics, S.A. Lysine demethylase inhibitors for thrombosis and cardiovascular diseases
CA2836394A1 (en) 2011-06-01 2012-12-06 Astrazeneca Ab Novel ticagrelor co - crystal
CA2839057A1 (en) 2011-06-15 2012-12-20 Actavis Group Ptc Ehf Improved process for preparing cyclopentylamine derivatives and intermediates thereof
CN102924457A (zh) * 2011-08-12 2013-02-13 上海恒瑞医药有限公司 三唑并嘧啶类衍生物、其制备方法及其用途
EP2570405A1 (en) 2011-09-14 2013-03-20 LEK Pharmaceuticals d.d. Synthesis of Triazolopyrimidine Compounds
HUE031673T2 (en) 2011-09-14 2017-07-28 Lek Pharmaceuticals Synthesis of triazolopyrimidine compounds
PE20141692A1 (es) 2011-10-20 2014-11-08 Oryzon Genomics Sa Compuestos de (hetero) aril ciclopropilamina como inhibidores de lsd1
EP2768805B1 (en) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
CA2852652A1 (en) 2011-10-27 2013-05-02 Lek Pharmaceuticals D.D. Synthesis of triazolopyrimidine compounds
EP2586773A1 (en) 2011-10-27 2013-05-01 LEK Pharmaceuticals d.d. Synthesis of Triazolopyrimidine Compounds
EP2589587A1 (en) 2011-11-04 2013-05-08 Chemo Ibérica, S.A. Synthesis of nitrogen substituted cyclopropanes
MX2014006190A (es) 2011-11-30 2014-07-10 Actavis Group Ptc Ehf Nueva forma cristalina de ticagrelor y proceso para la preparacion de la misma.
EP2607355A1 (en) * 2011-12-23 2013-06-26 LEK Pharmaceuticals d.d. Synthesis of triazolopyrimidine compounds
US9278972B2 (en) 2011-12-23 2016-03-08 Lek Pharmaceuticals D.D. Synthesis of triazolopyrimidine compounds
EP2628721A1 (en) 2012-02-20 2013-08-21 LEK Pharmaceuticals d.d. Synthesis of 2-(3,4-difluorophenyl)cyclopropanecarboxylic acid
EP2644590A1 (en) 2012-03-30 2013-10-02 LEK Pharmaceuticals d.d. Synthesis of 2-(3,4-difluorophenyl)cyclopropanamine derivatives and salts
CN104603098B (zh) 2012-03-30 2016-06-29 桑多斯股份公司 2-(3,4-二氟苯基)环丙胺衍生物和盐的合成
EP2834247A4 (en) 2012-04-05 2016-03-30 Reddys Lab Ltd Dr PREPARATION OF TICAGRELOR
WO2013163892A1 (en) * 2012-05-02 2013-11-07 Sunshine Lake Pharma Co., Ltd. Novel triazolo pyrimidine compounds and a process of preparation thereof
CN102659815B (zh) * 2012-05-04 2013-07-17 开原亨泰制药股份有限公司 一种制备选择性抗凝血药替卡格雷及其中间体的方法
EP2666771A1 (en) 2012-05-24 2013-11-27 LEK Pharmaceuticals d.d. Synthesis of Aminocyclopentanetriol Derivatives
ITMI20121142A1 (it) * 2012-06-28 2013-12-29 Chemo Iberica Sa Processo chemoenzimatico per la produzione di fenil ciclopropilammine
WO2014000719A1 (en) 2012-06-29 2014-01-03 Zentiva, K.S. Novel pharmaceutical solid forms of (1s,2s,3r,5s)-3-[7-[(1r,2s)-2-(3,4difluorophenyl)cyclopropylamino]-5-(propylthio)-3h-[1,2,3]triazolo[4,5-d]pyrimidin-3yl]-5-(2-hydroxyethoxy)cyclopentane-l,2-diol
CN104640864B (zh) * 2012-07-04 2016-11-16 力奇制药公司 替格瑞洛与二价金属盐的加合物
CN103626743B (zh) * 2012-08-23 2018-06-08 广东东阳光药业有限公司 替卡格雷的新型中间体及其制备方法
CN102875537A (zh) * 2012-09-10 2013-01-16 常州制药厂有限公司 一种新的抗血栓药物的制备方法
CZ2012705A3 (cs) 2012-10-16 2014-04-23 Zentiva, K.S. Pevná orální farmaceutická formulace obsahující ticagrelor
WO2014083139A1 (en) 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Novel amorphous form of ticagrelor
WO2014102830A1 (en) 2012-12-31 2014-07-03 Megafine Pharma (P) Ltd. A process for preparation of ticagrelor and intermediates thereof
CN104045620B (zh) * 2013-03-12 2017-05-10 博瑞生物医药（苏州）股份有限公司 一种替卡格雷中间体的制备方法
CZ307217B6 (cs) 2013-03-14 2018-04-04 Zentiva, K.S. Zlepšený způsob výroby a nové intermediáty syntézy ticagreloru
IN2013MU01111A (el) * 2013-03-25 2015-05-01 Glenmark Generics Ltd
ITMI20130487A1 (it) 2013-03-29 2014-09-30 Chemo Res S L Alchilazione selettiva di ciclopentilalcoli
CN107573333B (zh) 2013-04-10 2019-10-18 江苏恒瑞医药股份有限公司 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
WO2014170026A1 (en) 2013-04-18 2014-10-23 Zentiva, K.S. Stabilized amorphous ticagrelor
EP2813216A1 (en) 2013-06-10 2014-12-17 Zentiva, a.s. Stabilized amorphous ticagrelor
CN104230818B (zh) * 2013-06-06 2018-01-12 郝聪梅 替卡格雷中间体的改进制备方法
EP2816043A1 (en) 2013-06-21 2014-12-24 LEK Pharmaceuticals d.d. Spherical ticagrelor particles
WO2014206187A1 (zh) 2013-06-24 2014-12-31 苏州明锐医药科技有限公司 替卡格雷及其中间体的制备方法
CN104250251B (zh) * 2013-06-25 2017-05-17 上海京新生物医药有限公司 一种替格瑞洛的制备方法
WO2015001489A1 (en) 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Pharmaceutical compositions of ticagrelor
CZ2013866A3 (cs) 2013-11-08 2015-05-20 Zentiva, K.S. Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
WO2015110952A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof
CN103992323B (zh) * 2014-04-18 2017-03-29 南通常佑药业科技有限公司 一种替格瑞洛的制备方法
WO2015162630A1 (en) 2014-04-25 2015-10-29 Anlon Chemical Research Organization Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis.
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
EP3157907B1 (en) 2014-06-18 2018-08-29 Flamma S.P.A. Process for the preparation of triazolo[4,5-d]pyrimidine cyclopentane compounds
CN105272985B (zh) * 2014-06-24 2017-11-21 珠海联邦制药股份有限公司 三唑并[4,5‑d]嘧啶化合物及其合成方法、用途、组合物
WO2016001851A1 (en) * 2014-07-02 2016-01-07 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
US9982061B2 (en) 2014-10-01 2018-05-29 Medimmune Limited Antibodies to ticagrelor and methods of use
WO2016116942A1 (en) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
CN105985346B (zh) * 2015-03-06 2019-10-18 苏州朗科生物技术股份有限公司 一种新的替格瑞洛化合物制备方法及其中间体化合物
US9789087B2 (en) 2015-08-03 2017-10-17 Thomas Jefferson University PAR4 inhibitor therapy for patients with PAR4 polymorphism
CN105237540B (zh) * 2015-09-21 2017-10-03 南京正大天晴制药有限公司 一种替格瑞洛有关物质的制备方法、检测方法及用途
WO2017118633A1 (en) 2016-01-05 2017-07-13 Amneal Pharmaceuticals Company Gmbh Crystalline form of ticagrelor
TR201601835A2 (tr) 2016-02-12 2017-08-21 Ali Raif Ilac Sanayi Ve Ticaret Anonim Sirketi Ti̇kagrelor i̇çeren formülasyonlar i̇çi̇n üreti̇m yöntemi̇
US20170296666A1 (en) 2016-04-18 2017-10-19 Amneal Pharmaceuticals Company Gmbh Stable Pharmaceutical Composition Of Amorphous Ticagrelor
CN107595789B (zh) 2016-04-21 2021-01-15 阿斯利康(瑞典)有限公司 口腔崩解片
SG11201901619WA (en) * 2016-08-26 2019-03-28 Mitsubishi Tanabe Pharma Corp Bicyclic nitrogenated heterocyclic compound
US10905691B2 (en) 2016-09-09 2021-02-02 Université de Liège Use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection
EP3292867B1 (en) 2016-09-09 2019-05-15 Université de Liège Triazolo(4,5-d)pyrimidine derivatives for use in the prevention and treatment of bacterial infection
CN107814772A (zh) * 2017-11-24 2018-03-20 常州沃腾化工科技有限公司 4,6‑二氯‑5‑氨基‑2‑丙硫基嘧啶酯的精制方法
EP3527571A1 (en) * 2018-02-14 2019-08-21 Université de Liège Pyrimidine derivatives for prevention and treatment of bacterial infection
EP3829547A1 (en) 2018-07-27 2021-06-09 KRKA, d.d., Novo mesto Pharmaceutical composition of ticagrelor
CN109761785A (zh) * 2019-02-16 2019-05-17 安徽诺全药业有限公司 一种(1r，2r）-2-(3,4-二氟苯基)环丙烷羧酸的合成方法
GB201910656D0 (en) * 2019-07-25 2019-09-11 Univ Liege New use of triazolo(4,5-d)Pyrimidine deerivatives
EP3919497A1 (en) 2020-06-04 2021-12-08 Zaklady Farmaceutyczne Polpharma S.A. Process for the preparation of ticagrelor
CN112876485A (zh) * 2021-01-25 2021-06-01 郭丽伟 一种用于治疗子宫平滑肌高频率强直性收缩相关疾病的化合物
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
WO2023213198A1 (zh) * 2022-05-04 2023-11-09 华东师范大学 芳香稠环化合物作为trek-1激活剂的用途、包含其的药物组合物、镇痛剂

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3106578A (en) 1960-09-16 1963-10-08 Smith Kline French Lab Nu-phenethyl-2-phenylcyclopropylamine derivatives
SE329623B (el) 1967-06-08 1970-10-19 C F Boehringer Soehne Gmbh
DE1670265A1 (de) 1967-08-25 1971-01-28 Boehringer Mannheim Gmbh 2-Amino-Adenosinderivate und Verfahren zu deren Herstellung
CH558137A (de) 1971-05-17 1975-01-31 Ciba Geigy Ag Mittel zur beeinflussung des pflanzenwachstums.
US4016204A (en) * 1975-10-31 1977-04-05 Nelson Research & Development Company Method of synthesis of trans-2-phenylcyclopropylamine
US4543255A (en) 1984-05-10 1985-09-24 Southern Research Institute Carbocyclic analogs of purine 2'-deoxyribofuranosides
US4742064A (en) 1985-09-10 1988-05-03 Regents Of The University Of Minnesota Antiviral carbocyclic analogs of xylofuranosylpurines
AT397801B (de) 1988-01-20 1994-07-25 Univ Minnesota Didesoxydehydrocarbocyclische nucleoside und deren verwendung
EP0452360A4 (en) 1988-12-12 1992-05-20 Peter M. Palese Methods and compositions for the prophylaxis and treatment of hepatitis b virus infections
US5110933A (en) 1989-11-13 1992-05-05 Board Of Regents Of Oklahoma State University Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and precursors thereof
US5652366A (en) 1990-09-25 1997-07-29 Rhone-Poulenc Rorer Pharmaceuticals Inc. DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof
AU665184B2 (en) 1991-01-23 1995-12-21 Gensia, Inc. Adenosine kinase inhibitors
EP0508687B1 (en) 1991-04-06 1995-09-13 Astra Pharmaceuticals Limited ATP analogues
EP0521463A3 (en) 1991-07-04 1993-04-14 Hoechst Aktiengesellschaft Substituted cyclic cycloalkyltriols, process, intermediates for their preparation and their use as antiviral and antiparasitic agents
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US5817660A (en) 1991-12-06 1998-10-06 Hoechst Marion Roussel, Inc. Trans cyclopentanyl purine analogs useful as immunosuppressants
US5338725A (en) 1992-06-30 1994-08-16 The Research Foundation Of The State University Of New York Anti-aggregatory agents for platelets
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
DE69406649T2 (de) 1993-02-10 1998-03-05 Astra Pharmaceuticals Ltd., Kings Langley, Hertfordshire N-alkyl-2-substituierte atp-analoge
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US5620676A (en) 1994-03-08 1997-04-15 The United States Of America As Represented By The Department Of Health And Human Services Biologically active ATP analogs
US5831099A (en) 1995-03-10 1998-11-03 The United States Of America As Represented By The Secretary Of The Army Compounds of 1,5-disubstituted-3,7 diaza bicyclo 3.3.0! octanes and products containing the same
US5712258A (en) 1995-03-23 1998-01-27 The Trustees Of The University Of Pennsylvania Inotropic ADP and ATP analogues and their pharmaceutical compositions
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
JP4084415B2 (ja) 1995-07-11 2008-04-30 アストラゼネカ・アクチエボラーグ 新しい血小板凝集抑制剤
WO1997009330A1 (fr) 1995-09-01 1997-03-13 Hokuriku Seiyaku Co., Ltd. Cristal d'hydrate et son procede de preparation
ATE270331T1 (de) 1995-11-21 2004-07-15 Euroscreen Sa Rezeptor und dafür kodierendes nukleinsäuremolekül
US5948437A (en) 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
ATE213245T1 (de) 1996-12-20 2002-02-15 Triazolo(4,5-d)pyrimidinyl-derivate und ihre verwendung als medikamente
JPH10258654A (ja) 1997-03-18 1998-09-29 Delta Tsuuring:Kk リクライニングシート
SE9702775D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
SE9702772D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
SE9702773D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
AR017014A1 (es) * 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
SE9704709D0 (sv) 1997-12-17 1997-12-17 Astra Ab Pharmaceutically active compounds
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
DE60020010T2 (de) 1999-06-21 2006-01-19 Yamamoto Chemicals, Inc., Yao Polymethinverbindungen, Verfahren zu deren Herstellung und deren Verwendung
SE9903759D0 (sv) 1999-10-18 1999-10-18 Astra Ab Pharmaceutically active compounds
EP1775297A3 (en) 1999-11-12 2008-12-03 Biogen Idec MA Inc. Adenosine receptor antagonists and methods of making and using the same
GB0013407D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
US7040429B2 (en) 2001-10-10 2006-05-09 Invacare Corporation Wheelchair suspension
JP2005513099A (ja) 2001-12-21 2005-05-12 ファイザー・プロダクツ・インク アジスロマイシンの直接的に圧縮可能な配合品
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
US8563755B2 (en) 2008-09-09 2013-10-22 Astrazeneca Ab Process for preparing [1S-[1-α, 2-α, 3-β(1S*,2R*) 5-β]]-3-[7-[2-(3,4-difluorophenyl)-cyclopropylamino]-5-(propylthio)-3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl]-5-(2-hydroxyethoxy) cyclopentane-1,2-diol and to its intermediates
US8859769B2 (en) 2010-02-16 2014-10-14 Actavis Group Ptc Ehf Processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
CN103003231A (zh) 2010-06-30 2013-03-27 阿特维斯集团公司 制备苯基环丙基胺衍生物的新方法及其用于制备替卡格雷的用途
RU2013133879A (ru) 2010-12-20 2015-01-27 Актавис Груп Птс Ехф НОВЫЕ СПОСОБЫ ПОЛУЧЕНИЯ ТРИАЗОЛО[4, 5-d]ПИРИМИДИНА, ЕГО ПРОИЗВОДНЫЕ И ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ
CA2832570A1 (en) 2011-04-06 2012-10-11 Teva Pharmaceutical Industries Ltd. New intermediates and processes for preparing ticagrelor
CA2839057A1 (en) 2011-06-15 2012-12-20 Actavis Group Ptc Ehf Improved process for preparing cyclopentylamine derivatives and intermediates thereof
MX2014006190A (es) 2011-11-30 2014-07-10 Actavis Group Ptc Ehf Nueva forma cristalina de ticagrelor y proceso para la preparacion de la misma.
EP2834247A4 (en) 2012-04-05 2016-03-30 Reddys Lab Ltd Dr PREPARATION OF TICAGRELOR
WO2014083139A1 (en) 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Novel amorphous form of ticagrelor
WO2014102830A1 (en) 2012-12-31 2014-07-03 Megafine Pharma (P) Ltd. A process for preparation of ticagrelor and intermediates thereof
WO2014118808A2 (en) 2013-02-04 2014-08-07 Hetero Research Foundation Ticagrelor solid dispersion
CN107573333B (zh) 2013-04-10 2019-10-18 江苏恒瑞医药股份有限公司 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
WO2014195861A2 (en) 2013-06-04 2014-12-11 Dr. Reddy’S Laboratories Limited Preparation of ticagrelor
WO2016001851A1 (en) 2014-07-02 2016-01-07 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
EP3250207A1 (en) 2015-01-27 2017-12-06 Astrazeneca AB Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction

Also Published As

Publication number Publication date
IL210398A0 (en) 2011-03-31
ATE418547T1 (de) 2009-01-15
IL183969A (en) 2011-03-31
KR20010081054A (ko) 2001-08-25
US20130109702A1 (en) 2013-05-02
JP2002531567A (ja) 2002-09-24
CZ300280B6 (cs) 2009-04-08
HUS1300048I1 (hu) 2017-03-28
KR100822602B1 (ko) 2008-04-16
BRPI9915883B8 (pt) 2021-05-25
HUP0105081A2 (hu) 2002-05-29
IL198040A (en) 2015-06-30
ES2318081T3 (es) 2009-05-01
AR072756A2 (es) 2010-09-22
JP5415383B2 (ja) 2014-02-12
JP5043749B2 (ja) 2012-10-10
BR9915883A (pt) 2001-08-21
RU2593201C2 (ru) 2016-08-10
US20070265282A1 (en) 2007-11-15
HK1039933A1 (en) 2002-05-17
US20080214812A1 (en) 2008-09-04
RU2012121883A (ru) 2013-11-27
ATE261970T1 (de) 2004-04-15
CZ295234B6 (cs) 2005-06-15
PT1135391E (pt) 2004-07-30
EP2322513A2 (en) 2011-05-18
NO2022007I1 (no) 2022-03-23
AR023920A1 (es) 2002-09-04
US6974868B2 (en) 2005-12-13
LTPA2011004I1 (lt) 2022-04-11
DE122011100004I1 (de) 2011-09-08
ATE513816T1 (de) 2011-07-15
LTC1135391I2 (lt) 2022-04-11
IL169013A (en) 2015-10-29
NZ511778A (en) 2003-10-31
BRPI9915883B1 (pt) 2015-08-18
DE69915675T4 (de) 2012-08-30
NO319806B1 (no) 2005-09-19
CY1110501T1 (el) 2015-04-29
USRE46276E1 (en) 2017-01-17
US20120165348A1 (en) 2012-06-28
CA2351709C (en) 2010-04-06
KR100776484B1 (ko) 2007-11-28
CN1334816A (zh) 2002-02-06
ID29927A (id) 2001-10-25
JP2008266345A (ja) 2008-11-06
AU2016500A (en) 2000-06-26
EP1386917B1 (en) 2011-06-22
NO2011007I1 (no) 2011-06-06
SK7492001A3 (en) 2002-01-07
KR100742924B1 (ko) 2007-07-25
HUP0105081A3 (en) 2004-11-29
IL143232A (en) 2008-12-29
CN1128801C (zh) 2003-11-26
ES2216623T3 (es) 2004-10-16
KR20060091056A (ko) 2006-08-17
HK1039933B (zh) 2004-10-08
EP1135391A1 (en) 2001-09-26
HK1061684A1 (en) 2004-09-30
IL183969A0 (en) 2009-02-11
RU2317990C2 (ru) 2008-02-27
EP1135391B1 (en) 2004-03-17
PL201283B1 (pl) 2009-03-31
WO2000034283A1 (en) 2000-06-15
EP1386921B1 (en) 2008-12-24
US20100069408A1 (en) 2010-03-18
EP1386917A1 (en) 2004-02-04
NO20012725D0 (no) 2001-06-01
US20150152111A1 (en) 2015-06-04
US6525060B1 (en) 2003-02-25
TWI229674B (en) 2005-03-21
FR11C0016I1 (el) 2011-07-08
AR058967A2 (es) 2008-03-05
JP2011016831A (ja) 2011-01-27
EG24814A (en) 2010-09-21
DE69915675T2 (de) 2005-02-17
IL198040A0 (en) 2009-12-24
CA2351709A1 (en) 2000-06-15
CY1111759T1 (el) 2015-10-07
EP2322513A3 (en) 2011-08-24
EP1386921A1 (en) 2004-02-04
KR20070007971A (ko) 2007-01-16
EP1386909A1 (en) 2004-02-04
DK1135391T3 (da) 2004-06-28
ZA200104094B (en) 2002-08-19
SI1386921T1 (sl) 2009-04-30
CY2011005I1 (el) 2014-04-09
HU228589B1 (en) 2013-04-29
TR200101567T2 (tr) 2001-12-21
ES2366902T3 (es) 2011-10-26
RU2007133926A (ru) 2009-03-20
JP4202607B2 (ja) 2008-12-24
PT1386921E (pt) 2009-02-23
CZ300373B6 (cs) 2009-05-06
PL348724A1 (en) 2002-06-03
SA99200848B1 (ar) 2006-11-04
DK1386917T3 (da) 2011-08-29
AU766618B2 (en) 2003-10-23
CY2011005I2 (el) 2014-04-09
JP2007084551A (ja) 2007-04-05
US20140296258A1 (en) 2014-10-02
US20130072503A1 (en) 2013-03-21
DK1386921T3 (da) 2009-03-23
KR20070086540A (ko) 2007-08-27
SK286007B6 (sk) 2008-01-07
DE69915675D1 (de) 2004-04-22
US20060025590A1 (en) 2006-02-02
HK1061246A1 (en) 2004-09-10
SI1386917T1 (sl) 2011-09-30
US7250419B2 (en) 2007-07-31
NO20012725L (no) 2001-07-31
KR100764417B1 (ko) 2007-10-05
IL143232A0 (en) 2002-04-21
US20030144305A1 (en) 2003-07-31
DE69940171D1 (de) 2009-02-05
LU91819I2 (fr) 2011-08-01
FR11C0016I2 (fr) 2012-03-16
NO2011007I2 (no) 2012-07-09
MY121867A (en) 2006-02-28
CZ20011962A3 (cs) 2001-11-14

Similar Documents

Publication Publication Date Title
IL143232A0 (en) Novel triazolo (4,5-d) pyrimidine compounds
EG23758A (en) Pyrrolo (2,3-d) pyrimidine compounds
HK1026421A1 (en) Triazolo(4,5-d) pyrimidine derivatives as anti-thrombotic agents
HUP0102574A3 (en) Pyrrolo[2,3-d]pyrimidine compounds
HK1051195A1 (en) Pyrrolo(2,3-d)pyrimidine compounds.
IL137812A0 (en) Novel triazolo (4,5-d) pyrimidine compounds
PL355637A1 (en) Pyrazolo[1,5-d][1,2,4]triazines for enhancing cognition
SI1222195T1 (en) Novel thiazolo(4,5-d)pyrimidine compounds
SI1087970T1 (en) PYRROLO 2,3-d)PYRIMIDINE COMPOUNDS
SI0996621T1 (en) TRIAZOLO(4,5-d)PYRIMIDINE DERIVATIVES AS ANTI-THROMBOTIC AGENTS
ZA994004B (en) Pyrrolo[2,3-d]pyrimidine compounds.